2019. Cost effectiveness of pembrolizumab vs chemotherapy as first-line treatment for metastatic NSCLC that expresses high levels of PD-L1 in Switzerland. Swiss Medical Weekly. 149, 5152 (Dec. 2019), w20170. DOI:https://doi.org/10.4414/smw.2019.20170.